Similar articles for PMID: 30100989

Year	Number of Results
2002	2
2006	1
2008	3
2009	5
2010	11
2011	1
2012	4
2013	6
2014	5
2015	7
2016	7
2017	5
2018	2
2024	0

1

The DNA-polymorphism rs849142 is associated with skin toxicity induced by targeted anti-EGFR therapy using cetuximab.

Froelich MF, Stintzing S, Kumbrink J, Grünewald TGP, Mansmann U, Heinemann V, Kirchner T, Jung A. Froelich MF, et al. Oncotarget. 2018 Jul 13;9(54):30279-30288. doi: 10.18632/oncotarget.25689. eCollection 2018 Jul 13. Oncotarget. 2018. PMID: 30100989 Free PMC article.

2

Immunoglobulin G fragment C receptor polymorphisms and KRAS mutations: are they useful biomarkers of clinical outcome in advanced colorectal cancer treated with anti-EGFR-based therapy?

Paez D, Paré L, Espinosa I, Salazar J, del Rio E, Barnadas A, Marcuello E, Baiget M. Paez D, et al. Cancer Sci. 2010 Sep;101(9):2048-53. doi: 10.1111/j.1349-7006.2010.01621.x. Cancer Sci. 2010. PMID: 20550522 Free article.

3

Prognostic value of cetuximab-related skin toxicity in metastatic colorectal cancer patients and its correlation with parameters of the epidermal growth factor receptor signal transduction pathway: results from a randomized trial of the GERMAN AIO CRC Study Group.

Stintzing S, Kapaun C, Laubender RP, Jung A, Neumann J, Modest DP, Giessen C, Moosmann N, Wollenberg A, Kirchner T, Heinemann V. Stintzing S, et al. Int J Cancer. 2013 Jan 1;132(1):236-45. doi: 10.1002/ijc.27654. Epub 2012 Jun 26. Int J Cancer. 2013. PMID: 22644776 Free article. Clinical Trial.

4

Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer.

Graziano F, Ruzzo A, Loupakis F, Canestrari E, Santini D, Catalano V, Bisonni R, Torresi U, Floriani I, Schiavon G, Andreoni F, Maltese P, Rulli E, Humar B, Falcone A, Giustini L, Tonini G, Fontana A, Masi G, Magnani M. Graziano F, et al. J Clin Oncol. 2008 Mar 20;26(9):1427-34. doi: 10.1200/JCO.2007.12.4602. J Clin Oncol. 2008. PMID: 18349392

5

Biomarkers of skin toxicity induced by anti-epidermal growth factor receptor antibody treatment in colorectal cancer.

Kubo A, Hashimoto H, Takahashi N, Yamada Y. Kubo A, et al. World J Gastroenterol. 2016 Jan 14;22(2):887-94. doi: 10.3748/wjg.v22.i2.887. World J Gastroenterol. 2016. PMID: 26811634 Free PMC article. Review.

6

Correlation of FCGR3A and EGFR germline polymorphisms with the efficacy of cetuximab in KRAS wild-type metastatic colorectal cancer.

Pander J, Gelderblom H, Antonini NF, Tol J, van Krieken JH, van der Straaten T, Punt CJ, Guchelaar HJ. Pander J, et al. Eur J Cancer. 2010 Jul;46(10):1829-34. doi: 10.1016/j.ejca.2010.03.017. Epub 2010 Apr 24. Eur J Cancer. 2010. PMID: 20418097 Clinical Trial.

7

Association between EGFR gene polymorphisms, skin rash and response to anti-EGFR therapy in metastatic colorectal cancer patients.

Jaka A, Gutiérrez-Rivera A, Ormaechea N, Blanco J, La Casta A, Sarasqueta C, Izeta A, Tuneu A. Jaka A, et al. Exp Dermatol. 2014 Oct;23(10):751-3. doi: 10.1111/exd.12510. Exp Dermatol. 2014. PMID: 25039761

8

Association between serum ligands and the skin toxicity of anti-epidermal growth factor receptor antibody in metastatic colorectal cancer.

Takahashi N, Yamada Y, Furuta K, Nagashima K, Kubo A, Sasaki Y, Shoji H, Honma Y, Iwasa S, Okita N, Takashima A, Kato K, Hamaguchi T, Shimada Y. Takahashi N, et al. Cancer Sci. 2015 May;106(5):604-10. doi: 10.1111/cas.12642. Epub 2015 Apr 29. Cancer Sci. 2015. PMID: 25707609 Free PMC article. Clinical Trial.

9

Fc gamma receptor polymorphisms as predictive markers of Cetuximab efficacy in epidermal growth factor receptor downstream-mutated metastatic colorectal cancer.

Rodríguez J, Zarate R, Bandres E, Boni V, Hernández A, Sola JJ, Honorato B, Bitarte N, García-Foncillas J. Rodríguez J, et al. Eur J Cancer. 2012 Aug;48(12):1774-80. doi: 10.1016/j.ejca.2012.01.007. Epub 2012 Feb 2. Eur J Cancer. 2012. PMID: 22305465

10

Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.

Yen LC, Uen YH, Wu DC, Lu CY, Yu FJ, Wu IC, Lin SR, Wang JY. Yen LC, et al. Ann Surg. 2010 Feb;251(2):254-60. doi: 10.1097/SLA.0b013e3181bc9d96. Ann Surg. 2010. PMID: 20010090

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

48 results

Results by year